SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — History and Physical — Wilma Mankiller
| Patient | Wilma Mankiller |
|---|
| Date of birth | 1991-11-18 |
|---|
| Identifiers | MRN HR-ML052-SYN; SSN (made up) 000-52-4183 |
|---|
| Document date | 2026-03-09 |
|---|
| Author | Rena Hawkfeather-Lindqvist, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Visit
New patient with six weeks of drooping eyelids, double vision and fatigable weakness while recovering from a car crash: examination, ice pack test, breathing measurements, baseline tests, a pyridostigmine trial, kidney screening, and neuromuscular neurology referral [S]
History of Present Illness
This fictional modern episode addresses the presenting concerns below. [S]
- She wants to know why her eyelids droop and her arms give out, after a year of hard recovery. [S]
- She wants to keep working for her community. [S]
- She wants care that respects her as a Cherokee woman, close to home where possible, with her own medicine respected. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Wilma Pearl Mankiller was born on November 18, 1945, in Tahlequah, Oklahoma, the capital of the Cherokee Nation, the sixth of eleven children; her father was a full-blood Cherokee. A Cherokee Nation release gave her birthplace as the W.W. Hastings Indian Hospital in Tahlequah; the Oklahoma Hall of Fame says she was born at Rock Mountain in Adair County. [D]
- As a child she moved with her family from Mankiller Flats in Adair County to San Francisco under the Bureau of Indian Affairs relocation program (1956 or 1957 by different accounts); she later described the move as her own little Trail of Tears. [D]
- The occupation of Alcatraz Island in 1969 and her work with American Indian communities in California in the 1970s set the course of her activism. [D]
- She returned to eastern Oklahoma with her two daughters in the later 1970s (1976 or 1977 by different accounts), worked for the Cherokee Nation, and lived on her grandfather's allotment, Mankiller Flats, in Adair County. [D]
- In 1979 she was nearly killed in a head-on car crash on a curve, in which the driver of the other car, one of her best friends, died. She needed about 17 operations; accounts say her leg was barely saved from amputation and that she was told she might never walk again. The Oklahoma Hall of Fame dates the crash to 1978 and describes shattered legs, broken ribs and a crushed face. [D]
- Her recovery was made harder by the emotional trauma of her friend's death in the crash. [D]
8 later historical claims are omitted because they describe events after the index age. See the teaching note.
Past Medical History
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|
| 1979 (1978 in one account) | Near-fatal head-on car crash with about 17 operations, with fractures of the legs, ribs and face | D (CLM-0005) |
Family History
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
Social History
- Cherokee Nation citizen; lives at Mankiller Flats in Adair County, on land long held by her family; works for the Cherokee Nation on rural community development and has returned to part-time work since the crash [S]
- Household: lives with her two daughters, who are not named and are given no role in her care [S]
- Tobacco: never. Alcohol: none. No drug use [S]
- Health care: eligible for Cherokee Nation Health Services as a citizen; prefers laboratory work at a Cherokee Nation clinic near her home; drives herself again since the winter, about an hour to this clinic [S]
- Traditional medicine: she has her own Cherokee medicine and will decide whether and how it is part of her care; she shares any plant medicines with the clinic so that interactions can be checked; nothing further is asked or recorded [S]
- Strengths: determination through a long recovery, deep ties to her community, and a practical way of solving problems [S]
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Pyridostigmine bromide 30 mg oral tablet, one tablet three times daily with meals as a trial; take 30 to 45 minutes before eating | One tablet three times daily | Oral route | 2026-03-09 to 2026-03-23 | completed | S |
| Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg pain | One or two tablets up to three times daily as needed | Oral route | 2025-09-15 | active | S |
Review of Systems
Positive for the concerns in the history of present illness. Alert, direct and composed; tired; speaks of the hard year since the crash and the loss of her friend; PHQ-9 score 7. No other systems reported as affected in this synthetic episode. [S]
General Status
Alert and engaged. Independent in daily activities; walks without help indoors and with a cane on rough ground after the leg operations; by evening she tires holding her arms up to brush her hair and must rest her jaw while eating. [S]
Physical Exam
Vital signs recorded on 2026-03-09; see the Vital Signs section. Mental status: Alert, direct and composed; tired; speaks of the hard year since the crash and the loss of her friend; PHQ-9 score 7. The physical examination is limited to the findings relevant to this synthetic episode. [S]
Vital Signs
| Date | Measure | Value | Unit | Provenance |
| 2026-03-09 | Body height | 163 | cm | S |
| 2026-03-09 | Body weight | 61.8 | kg | S |
| 2026-03-09 | Body mass index (BMI) [Ratio] | 23.3 | kg/m2 | S |
| 2026-03-09 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-03-09 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-03-09 | Heart rate | 78 | /min | S |
| 2026-03-09 | Respiratory rate | 16 | /min | S |
| 2026-03-09 | Body temperature | 36.7 | Cel | S |
| 2026-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 2026-03-09 | Hemoglobin [Mass/volume] in Blood | 12.8 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-03-09 | Leukocytes [#/volume] in Blood by Automated count | 6.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-03-09 | Platelets [#/volume] in Blood by Automated count | 262 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-03-09 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-09 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-09 | Glucose [Mass/volume] in Serum or Plasma | 88 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-09 | Creatinine [Mass/volume] in Serum or Plasma | 0.78 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-03-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 102 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-09 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-03-09 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | 7-45 U/L | Normal | S |
| 2026-03-09 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 8-43 U/L | Normal | S |
| 2026-03-09 | Albumin [Mass/volume] in Serum or Plasma | 4.2 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-03-09 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-03-09 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.3 | % | <=5.6% | Normal | S |
| 2026-03-09 | Albumin/Creatinine [Mass Ratio] in Urine | 14 | mg/g | Below 30 mg/g is normal (A1) | Normal | S |
| 2026-03-09 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 31 | ng/mL | 30-100 ng/mL | Normal | S |
| 2026-03-09 | Forced vital capacity [Volume] Respiratory system | 3.3 | L | Lower limit of normal about 2.9 L for her age, sex and height | Normal | S |
| 2026-03-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | | | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Drooping eyelids and double vision for six weeks, worse in the evening, with fatigable weakness of the arms and neck, tiring when chewing and a nasal voice after long talks; a disorder of the neuromuscular junction suspected | active | confirmed |
H53.2 | S — Synthetic presenting problem, resolved at the second visit when antibodies and nerve testing established myasthenia gravis. |
| Autosomal dominant polycystic kidney disease (hereditary, as she has described it), with normal kidney function; to be staged | active | confirmed |
Q61.2 | S — The hereditary polycystic kidney disease is documented (D) from her later public account; its detection before the index date, and every value, are synthetic. |
| Recovery from major trauma in a head-on car crash last year: fractures of both legs, ribs and face, with many operations; walks independently, with a cane on rough ground | active | confirmed |
Z87.81 | S — The crash, the operations and the injuries are documented (D); the current function is synthetic. |
Assessment
- Drooping eyelids and double vision for six weeks, worse in the evening, with fatigable weakness of the arms and neck, tiring when chewing and a nasal voice after long talks; a disorder of the neuromuscular junction suspected: active, confirmed [S]
- Autosomal dominant polycystic kidney disease (hereditary, as she has described it), with normal kidney function; to be staged: active, confirmed [S]
- Recovery from major trauma in a head-on car crash last year: fractures of both legs, ribs and face, with many operations; walks independently, with a cane on rough ground: active, confirmed [S]
Plan of Treatment
- Neuromuscular neurology consultation within two weeks for suspected generalized myasthenia gravis: diagnosis, immunotherapy, thymectomy and safety. Guideline: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016) [S]
- Diagnostic tests: acetylcholine receptor binding antibodies (MuSK antibodies if negative), repetitive nerve stimulation (single-fiber EMG if unclear), CT of the chest with contrast for thymoma, TSH, and seated FVC with negative inspiratory force. Guideline: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016) [S]
- Safety: pyridostigmine 30 mg three times daily as a trial; warning signs of myasthenic crisis (breathlessness lying flat, weak cough, trouble swallowing, slurred speech) with emergency care the same day; a wallet card and the list of medicines to avoid, including fluoroquinolones, aminoglycosides, macrolides, magnesium by vein, beta-blockers and telithromycin. Guideline: Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); Cautionary Drugs (medicines that may worsen myasthenia gravis) (2026) [S]
- Kidney care for her hereditary polycystic kidney disease: kidney ultrasound with total kidney volume, eGFR and urine albumin, home blood pressure readings, 2 to 3 liters of water a day spread through the day, less salt, and acetaminophen instead of NSAIDs. Guideline: KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 2025;107(2S):S1-S239 (2025) [S]
- Culturally safe care: laboratory work at a Cherokee Nation Health Services clinic near her home, results shared with this clinic; time given to explain each test and medicine plainly; her own Cherokee medicine respected, with any plant medicine shared so that interactions can be checked, and nothing further asked. Guideline: Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); Cherokee Nation Health Services (2026) [S]
- Referral to neuromuscular neurology, Marcus Okafor-Delaney, MD, ordered 2026-03-09 [S]